A prospective randomised clinical trial of the intra-operative use of 5-fluorouracil on the outcome of dupuytren's disease.
5-Fluorouracil reduces proliferation rates of fibroblasts, myofibroblast differentiation and contractility of ocular fibroblasts in vitro. This double-blind randomized clinical trial assesses whether intra-operative topical treatment with 5-fluorouracil reduces the recurrence rate after limited excision of Dupuytren's tissue. Patients with two-digit disease were randomized to having 5-fluorouracil (25mg/ml) treatment for 5 minutes on one digit and placebo on the other. Fifteen patients were enrolled with 18 months follow-up. There were no peri-operative complications. Wound healing was not delayed and there was no deterioration in the flexion deformity of the 5-fluorouracil treated digits. Patients were subsequently assessed by joint angle measurement at 3, 6, 12 and 18 months. There was no significant difference between control and 5-fluorouracil treated digits.
Bulstrode
N W
NW
From the RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood, HA6 2RN, UK.
Bisson
M
M
Jemec
B
B
Pratt
A L
AL
McGrouther
D A
DA
Grobbelaar
A O
AO
D000963:Antimetabolites / Q000627:therapeutic use*; D004311:Double-Blind Method; D004387:Dupuytren Contracture / Q000188:drug therapy* / Q000601:surgery; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome
D000963:Antimetabolites; D005472:Fluorouracil